AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- Overexpression of the cell-cycle regulator and estrogen-receptor alpha co-factor, cyclin D1, appears to predict tamoxifen resistance in breast cancer tumors, pathologists in Sweden report.
Tamoxifen is used as adjuvant therapy for estrogen-receptor alpha (ERalpha) positive breast cancer. But even though they express ERalpha, some tumors are resistant to tamoxifen's affects.
In their study, M. Stendahl and colleagues at Lund University and Malmo University Hospital "delineated the potential link between ... cyclin D1 and tamoxifen response in a material of 167 postmenopausal breast cancers arranged in a tissue array."
Samples came from patients who had been randomized to receive either 2 years of tamoxifen treatment or no treatment. Median follow-up was 18 years.
"Interestingly," noted Stendahl and team, "in the 55 strongly ERalpha-positive samples with moderate or low cyclin D1 levels, patients responded to tamoxifen treatment, whereas the 46 patients with highly ERalpha-positive and cyclin D1 overexpressing tumors did not show any difference in survival between tamoxifen and no treatment."
They found that untreated patients ...
Source: HighBeam Research, Cyclin D1 overexpression appears to predict tamoxifen resistance.